LV11971B - Pirolidīnhidroksāmskābes atvasinājumi un to iegūšanas paņēmiens - Google Patents
Pirolidīnhidroksāmskābes atvasinājumi un to iegūšanas paņēmiens Download PDFInfo
- Publication number
- LV11971B LV11971B LVP-97-203A LV970203A LV11971B LV 11971 B LV11971 B LV 11971B LV 970203 A LV970203 A LV 970203A LV 11971 B LV11971 B LV 11971B
- Authority
- LV
- Latvia
- Prior art keywords
- hydroxy
- phenyl
- acetamide
- hydrogen
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Claims (13)
1LV 11971 Izgudrojuma formula 1. Savienojums ar formulu (I), Ar
A ir ūdeņraža atoms, hidroksilgrupa vai OY, kur Y ir hidroksilgrupas aiz-sarggrupa; Ar ir fenilgrupa, kas neobligāti aizvietota ar vienu vai vairākiem aizvietotājiem no rindas: halogēna atoms, hidroksilgrupa, Ci^alkilgrupa, Ci^alk-oksigrupa, trifluormetilgrupa, Ci^alkoksi-Ci^alkoksigrupa un karboksil-aizvietota Ci^alkoksigrupa; X ir fenilgrupa, naftilgrupa, bifenilgrupa, indanilgrupa, benzofuranilgrupa, benzotienilgrupa, 1-oksotetralin-6-iigrupa, Ci-*alkilendioksigrupa, piri-dinilgrupa, furanilgrupa vai tienilgrupa, pie kam minētas grupas neobligāti aizvietotas ar 1 - 3 aizvietotājiem no rindas: halogēna atoms, Ci^alkilgrupa, Ci^alkoksigrupa, hidroksilgrupa, nitrogrupa, trifluormetilgrupa un metilsulfonilgrupa; R ir ūdeņraža atoms, Ci^alkilgrupa vai hidroksilgrupas aizsarggrupa, kā arī minētā savienojuma sālis.
2. Savienojums pēc 1. punkta, kurā A ir ūdeņraža atoms vai hidroksilgrupa; R ir ūdeņraža atoms vai C-Malkilgrupa.
3. Savienojums pēc 2. punkta, kurā Ar ir fenilgrupa. 2
4. Savienojums pēc 3. punkta, kurā X ir fenilgrupa, kas aizvietota ar 1 - 3 aizvietotājiem no rindas: hlora atoms, metilgrupa un trifluormetilgrupa; R ir ūdeņraža atoms.
5. Savienojums pēc 4. punkta, kurā X ir 3,4-dihlorfenilgrupa.
6. Savienojums pēc 4. punkta, kas ņemts no rindas: 2-(3,4-dihlorfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etilļacetamTds; 2-(2,3,6-trihlorfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etil]acetamTds; 2-(4-trifluormetilfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etiljacetamīds; 2-(2,4,6-trimetilfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etilļacetamīds; 2-(3,4-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feni!etii]- acetamīds; 2-{4-bromfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(4-trifluormetilfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(4-hlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletilj- acetamīds; 2-(2,3-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(2,4-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamTds; 2-(2,5-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(2,6-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletilļ- acetamīds; 2-(2,3,6-trihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(3,4-dihlorfenil)-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]-acetamīds; 2-(3,4-dimetilfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamTds. 3 LV 11971
7. Savienojums pēc 1. punkta, kurā A ir OY un R ir hidroksilgrupas aizsarggrupa no rindas: benzilgrupa, trifenilmetilgrupa, tetrahidropiranilgrupa, metoksimetilgrupa un R1R2R3Si- grupa, kur katrs no R1, R2 un Rs ir Ci^alkil-grupa vai fenilgrupa.
8. Farmaceitiskā kompozīcija, kas satur savienojumu pēc 1. punkta un farmaceitiski inertu nesēju, un kas pielietojama kā analgētisks, pretiekaisuma, diurētisks, anestētisks, neiroprotektīvs līdzeklis, līdzeklis triekas ārstēšanai vai līdzeklis tādu funkcionālu zarnu slimību kā vēdersāpju ārstēšanai.
9. Savienojuma pēc 1. punkta pielietojums tādu ārstniecības līdzekļu ražošanai, kas paredzēti tādu zīdītājus slimību ārstēšanai, kurās nepieciešams kapa-receptora agonists.
10. Savienojums ar formulu (II), Ar
kurā: A ir ūdeņraža atoms, hidroksilgrupa vai OY, kur Y ir hidroksilgrupas aizsarggrupa Ar ir fenilgrupa, neobligāti aizvietota ar vienu vai vairākiem aizvietotājiem no rindas: halogēna atoms, hidroksilgrupa, Ci^alkilgrupa, Ci^alkoksi-grupa, trifluormetilgrupa, Ci^alkoksi-Ci^alkoksigrupa un karboksilaizvie-tota C-Malkoksigrupa; R ir ūdeņraža atoms, Ci^alkilgrupa vai hidroksilgrupas aizsarggrupa.
11. Paņēmiens savienojuma ar formulu (II) iegūšanai, kas ietver etanolamīna (III) reakciju ar hidroksilamīna atvasinājumu (IV),
(V) 4 kuru tālāk apstrādā ar metānsulfonilhlorīdu bāzes klātbūtnē, un pēc tam pievieno aizsargātu hidroksilamīnu, noslēgumā, ja nepieciešams, nošķeļot aizsarggrupu.
12. Paņēmiens savienojuma ar formulu (II) iegūšanai, kas ietver pirolidTna ar formulu (VII) apstrādi ar aizvietotu vai neaizvietotu feniloksirānu (VIII),
O (vil) (vm) veidojot savienojumu (IX) un (X) maisījumu,
kuru apstrādā ar metānsulfonilhlorīdu bāzes klātbūtnē un pievieno aizsargātu hidroksilamīnu, noslēgumā, ja nepieciešams, nošķeļot aizsarggrupu.
13. Paņēmiens savienojuma ar formulu (I) iegūšanai, kas ietver savienojuma ar formulu (II), kurā R ir hidroksilgrupas aizsarggrupa, apstrādi ar karbonskābi XCH2COOH, aizsarggrupas atšķelšanu, un, ja nepieciešams, iegūtā savienojuma alkilēšanu.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9500631 | 1995-03-31 | ||
PCT/JP1996/000820 WO1996030339A1 (en) | 1995-03-31 | 1996-03-28 | Pyrrolidinyl hydroxamic acid compounds and their production process |
Publications (2)
Publication Number | Publication Date |
---|---|
LV11971A LV11971A (lv) | 1998-02-20 |
LV11971B true LV11971B (lv) | 1998-06-20 |
Family
ID=14125824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-97-203A LV11971B (lv) | 1995-03-31 | 1997-10-21 | Pirolidīnhidroksāmskābes atvasinājumi un to iegūšanas paņēmiens |
Country Status (35)
Country | Link |
---|---|
US (2) | US5952369A (lv) |
EP (1) | EP0817772B1 (lv) |
JP (1) | JP3035356B2 (lv) |
KR (1) | KR100258657B1 (lv) |
AP (1) | AP625A (lv) |
AR (1) | AR002729A1 (lv) |
AT (1) | ATE231840T1 (lv) |
AU (1) | AU693336B2 (lv) |
BG (1) | BG62611B1 (lv) |
BR (1) | BR9607750A (lv) |
CA (1) | CA2213815C (lv) |
CZ (1) | CZ306497A3 (lv) |
DE (1) | DE69626009T2 (lv) |
DK (1) | DK0817772T3 (lv) |
ES (1) | ES2188743T3 (lv) |
HR (1) | HRP960141A2 (lv) |
HU (1) | HUP9900767A3 (lv) |
IL (2) | IL117440A0 (lv) |
IS (1) | IS4547A (lv) |
LV (1) | LV11971B (lv) |
MA (1) | MA23832A1 (lv) |
NO (1) | NO974513L (lv) |
NZ (1) | NZ304113A (lv) |
OA (1) | OA10518A (lv) |
PE (1) | PE43397A1 (lv) |
PL (1) | PL322652A1 (lv) |
RU (1) | RU2144917C1 (lv) |
SI (1) | SI9620039A (lv) |
SK (1) | SK129897A3 (lv) |
TN (1) | TNSN96045A1 (lv) |
TR (1) | TR199701082T1 (lv) |
TW (1) | TW408111B (lv) |
WO (1) | WO1996030339A1 (lv) |
YU (1) | YU18696A (lv) |
ZA (1) | ZA962476B (lv) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9701042A (es) * | 1996-02-07 | 1998-05-31 | Pfizer | Compuestos del acido hidroxamico. |
TNSN97092A1 (ar) * | 1996-09-18 | 1999-12-31 | Agouron Pharma | مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة. |
CA2273253C (en) * | 1996-12-02 | 2003-09-16 | Kyorin Pharmaceutical Co., Ltd. | Novel n-substituted pyrrolidine derivatives and process for preparing the same |
CA2276074A1 (en) * | 1997-01-10 | 1998-07-16 | Merck & Co., Inc. | Efficient synthesis of a chiral mediator |
IL130429A0 (en) * | 1998-08-24 | 2000-06-01 | Pfizer Prod Inc | Process for preparing pyrrolidinyl hydroxamic acid compounds |
KR100295740B1 (ko) * | 1998-09-17 | 2001-11-05 | 박영구 | N-치환된-하이드록시고리화알킬아민유도체의제조방법 |
US6444829B1 (en) * | 2000-07-19 | 2002-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine compounds |
AU2002247886A1 (en) | 2001-04-30 | 2002-11-11 | Pfizer Products Inc. | Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists |
US7091357B2 (en) * | 2001-12-26 | 2006-08-15 | University Of Kentucky Research Foundation | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies |
AU2003269399A1 (en) * | 2002-11-01 | 2004-05-25 | Pfizer Products Inc. | Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination |
GB0821010D0 (en) * | 2008-11-17 | 2008-12-24 | Univ Warwick | Plant development control composition |
EP2709985B1 (en) | 2011-05-16 | 2017-10-04 | Bionomics Limited | Amine derivatives as potassium channel blockers |
CA2866299C (en) * | 2012-03-05 | 2017-12-05 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists |
GB201210395D0 (en) * | 2012-06-11 | 2012-07-25 | Syngenta Participations Ag | Crop enhancement compositions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3268539A (en) * | 1963-05-20 | 1966-08-23 | Universal Oil Prod Co | Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters |
-
1996
- 1996-03-11 IL IL11744096A patent/IL117440A0/xx unknown
- 1996-03-14 AP APAP/P/1996/000791A patent/AP625A/en active
- 1996-03-15 TW TW085103136A patent/TW408111B/zh active
- 1996-03-25 MA MA24191A patent/MA23832A1/fr unknown
- 1996-03-25 PE PE1996000208A patent/PE43397A1/es not_active Application Discontinuation
- 1996-03-26 HR HRPCT/JP95/631A patent/HRP960141A2/hr not_active Application Discontinuation
- 1996-03-27 YU YU18696A patent/YU18696A/sh unknown
- 1996-03-28 ES ES96907686T patent/ES2188743T3/es not_active Expired - Lifetime
- 1996-03-28 KR KR1019970706880A patent/KR100258657B1/ko not_active IP Right Cessation
- 1996-03-28 HU HU9900767A patent/HUP9900767A3/hu unknown
- 1996-03-28 ZA ZA9602476A patent/ZA962476B/xx unknown
- 1996-03-28 DK DK96907686T patent/DK0817772T3/da active
- 1996-03-28 CA CA002213815A patent/CA2213815C/en not_active Expired - Fee Related
- 1996-03-28 AU AU51211/96A patent/AU693336B2/en not_active Ceased
- 1996-03-28 SI SI9620039A patent/SI9620039A/sl not_active IP Right Cessation
- 1996-03-28 BR BR9607750A patent/BR9607750A/pt active Search and Examination
- 1996-03-28 NZ NZ304113A patent/NZ304113A/xx unknown
- 1996-03-28 US US08/913,823 patent/US5952369A/en not_active Expired - Fee Related
- 1996-03-28 AT AT96907686T patent/ATE231840T1/de not_active IP Right Cessation
- 1996-03-28 SK SK1298-97A patent/SK129897A3/sk unknown
- 1996-03-28 EP EP96907686A patent/EP0817772B1/en not_active Expired - Lifetime
- 1996-03-28 WO PCT/JP1996/000820 patent/WO1996030339A1/en active IP Right Grant
- 1996-03-28 DE DE69626009T patent/DE69626009T2/de not_active Expired - Fee Related
- 1996-03-28 TR TR97/01082T patent/TR199701082T1/xx unknown
- 1996-03-28 PL PL96322652A patent/PL322652A1/xx unknown
- 1996-03-28 RU RU97117590A patent/RU2144917C1/ru active
- 1996-03-28 CZ CZ973064A patent/CZ306497A3/cs unknown
- 1996-03-28 JP JP08529174A patent/JP3035356B2/ja not_active Expired - Fee Related
- 1996-03-29 AR ARP960101993A patent/AR002729A1/es unknown
- 1996-03-29 TN TNTNSN96045A patent/TNSN96045A1/fr unknown
-
1997
- 1997-08-19 IS IS4547A patent/IS4547A/is unknown
- 1997-09-17 BG BG101896A patent/BG62611B1/bg unknown
- 1997-09-29 NO NO974513A patent/NO974513L/no not_active Application Discontinuation
- 1997-09-30 OA OA70091A patent/OA10518A/en unknown
- 1997-10-21 LV LVP-97-203A patent/LV11971B/lv unknown
-
1999
- 1999-04-15 IL IL12947999A patent/IL129479A0/xx unknown
- 1999-04-29 US US09/302,097 patent/US6110947A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2125041C1 (ru) | Арилацетамиды, способ их получения, фармацевтическая композиция и способ ее получения | |
US5071859A (en) | N-substituted azaheterocyclic carboxylic acids and pharmaceutical uses | |
EP0817772B1 (en) | Pyrrolidinyl hydroxamic acid compounds and their production process | |
Jackson et al. | A New Approach to the Synthesis of. beta.-Hydroxy-. alpha.-amino Acids Using (Arylthio) nitrooxiranes | |
KR101124098B1 (ko) | 2-옥소-1-피롤리딘 유도체를 제조하는 방법 | |
KR100523184B1 (ko) | 아제티딘 및 피롤리딘의 유도체 | |
JP2935899B2 (ja) | ▲下k▼レセプターアゴニストとしてのn−(2−(ピロリジニル−1)−1−フェニルエチル)アセトアミド | |
FR2729142A1 (fr) | Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques | |
NZ233002A (en) | 3-(aminoalkyl)benzothiopyran derivatives and pharmaceutical compositions | |
EP0789021B1 (en) | Hydroxamic acid compounds as opioid kappa receptor agonists | |
MXPA97007454A (en) | Hydroxamic pirrolidinil acid compounds and their product procedure | |
US5214057A (en) | N-substituted azaheterocyclic carboxylic acids | |
JP2012107006A (ja) | N−置換−環状アミノ誘導体の製造方法 | |
PT789021E (pt) | Compostos de acido pirrolidinil hidroxamico e o processo para a sua producao |